No proof of any other drugs showing superiority to Bryostatin. That requires a blinded placebo-controlled trial, which we have.
What NTRP is trying to do with Bryostatin is revolutionary. We've shown in a placebo-controlled trial, that moderate-to-severe patients IMPROVED in their SIB score. That has never been done before, and it's nothing that any of the competition can claim. Further, by eliminating the memantine patients, the treatment effect is increased almost 3-fold.
When Bryostatin is used long-term, as was done with our compassionate-use patients (moderate-to-severe), the improvements were miraculous. We have seen patients' MMSE scores improve by several points and restoration of activities of daily living. With long-term use of Bryostatin, such as we saw with these CU patients, I believe we will see the same life-changing properties of Bryostatin shine through.
Finally, Bryostatin was administered safely in the phase 2b trial for 15 weeks, and has been administered safely in other trials for over a year at higher doses.
What NTRP is trying to do with Bryostatin is revolutionary. We've shown in a placebo-controlled trial, that moderate-to-severe patients IMPROVED in their SIB score. That has never been done before, and it's nothing that any of the competition can claim. Further, by eliminating the memantine patients, the treatment effect is increased almost 3-fold.
When Bryostatin is used long-term, as was done with our compassionate-use patients (moderate-to-severe), the improvements were miraculous. We have seen patients' MMSE scores improve by several points and restoration of activities of daily living. With long-term use of Bryostatin, such as we saw with these CU patients, I believe we will see the same life-changing properties of Bryostatin shine through.
Finally, Bryostatin was administered safely in the phase 2b trial for 15 weeks, and has been administered safely in other trials for over a year at higher doses.
